SV Health Investors and RA Capital Management led a $115m Series D round in Artios.

SV Health Investors, a specialist healthcare fund manager, and RA Capital Management, a multi-stage investment manager, led a $115m Series D round in Artios, a biopharmaceutical company, with participation from Andera Partners, Avidity Partners, EQT Life Sciences, Invus, IP Group plc, Janus Henderson Investors, M Ventures, Novartis Venture Fund, Omega Funds, Pfizer Ventures, Piper Heartland, Sofinnova Partners, and Schroders Capital. “This Series D accelerates our potential path to registration for both alnodesertib and ART6043, broadening development for the next generation of DNA damage response (DDR) therapeutics to indications among the highest of unmet need across pancreatic, colorectal, and breast cancers, where median survival is often measured in months,” Mike Andriole, Artios CEO.